@article{f1ce4441fc844e5bb3e774a0868a376c,
title = "Predicting progression to Alzheimer's disease with human hippocampal progenitors exposed to serum",
abstract = "Adult hippocampal neurogenesis is important for learning and memory and is altered early in Alzheimer's disease. As hippocampal neurogenesis is modulated by the circulatory systemic environment, evaluating a proxy of how hippocampal neurogenesis is affected by the systemic milieu could serve as an early biomarker for Alzheimer's disease progression. Here, we used an in vitro assay to model the impact of systemic environment on hippocampal neurogenesis. A human hippocampal progenitor cell line was treated with longitudinal serum samples from individuals with mild cognitive impairment, who either progressed to Alzheimer's disease or remained cognitively stable. Mild cognitive impairment to Alzheimer's disease progression was characterized most prominently with decreased proliferation, increased cell death and increased neurogenesis. A subset of 'baseline' cellular readouts together with education level were able to predict Alzheimer's disease progression. The assay could provide a powerful platform for early prognosis, monitoring disease progression and further mechanistic studies.",
keywords = "Alzheimer{\textquoteright}s disease, hippocampal progenitors, neurogenesis, prognostic biomarker",
author = "Aleksandra Maruszak and Edina Silajd{\v z}i{\'c} and Hyunah Lee and Tytus Murphy and Benjamine Liu and Liu Shi and {de Lucia}, Chiara and Abdel Douiri and Evgenia Salta and Nevado, {Alejo J.} and Teunissen, {Charlotte E.} and Visser, {Pieter J.} and Jack Price and Henrik Zetterberg and Simon Lovestone and Sandrine Thuret",
note = "Funding Information: We would like to thank the many research teams across Europe collecting samples for this and other AddNeuroMed studies. We would also like to thank Rufina Leung for managing sample collection and distribution at the London site. A.D. acknowledges financial support from the National Institute for Health Research (NIHR) Biomedical Research and from the NIHR Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust CLAHRC. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Funding Information: This work has been funded by grants provided by the John and Lucille van Geest Foundation (A.M.), the Medical Research Council UK (MR/K500811/1) and the Cohen Charitable Trust (T.M.), the Medical Research Councils UK (MR/N030087/1; MR/S00484X/1; MC_PC_18052) (S.T.), the Galen and Hilary Weston Foundation (E.d.S., H.L.) and the Rhodes Trust (B.L.). This study received support for sample collection, biomarker studies and data analysis from Alzheimer{\textquoteright}s Research UK (S.L.), through the AddNeuroMed program funded by EU FP6 program (S.L.) and with support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement n_115372 (S.L.), resources of which are composed of financial contribution from the European Union{\textquoteright}s Seventh Framework Program (FP7/2007-2013) and EFPIA companies{\textquoteright} in-kind contribution. E.v.S. receives funding from Alzheimer Nederland and Health Holland. H.Z. is a Wallenberg Scholar. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Publisher Copyright: {\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.",
year = "2023",
month = may,
day = "1",
doi = "https://doi.org/10.1093/brain/awac472",
language = "English",
volume = "146",
pages = "2045--2058",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "5",
}